Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elevation debuts with tumor-agnostic mAb in Phase II

Elevation Oncology’s lead program is in development for NRG1 fusion-driven solid tumors

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners.

Elevation Oncology Inc. is developing therapies for cancers driven by rare mutations, starting with solid tumors with NRG1 fusions. Founder and CBO Shawn Leland told BioCentury the mutation is only present in about 0.2% of all solid tumors.

The start-up is collaborating with next-generation sequencing companies Ashion Analytics LLC, Strata Oncology Inc., Tempus Labs Inc.

Read the full 819 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers